XClose

EMINENT CONSORTIUM

Home
Menu

Experimental Medicine Initiative to Explore New Therapies (EMINENT)

EMINENT represents a unique collaborative network, funded up to £8M by the MRC matched in-kind by GSK.

Accessing GSK's clinic ready portfolio to enable translational discovery

Bringing together investigators from University College London (UCL), the University of Cambridge, the University of Glasgow, the University of Newcastle, Imperial College London and GlaxoSmithKline (GSK), with unprecedented access to GSK's unlicenced clinic-ready asset portfolio to enable experimental medicine studies aimed at enhancing understanding of disease mechanisms and accelerating development of novel therapeutics for patients in under-served disease areas.